Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Subcutaneous Abatacept Withdrawal in RA
NCT00533897Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2007
- Primary completion
- Dec 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of abatacept in rheumatoid arthritis (RA), sponsored by Bristol Myers Squibb. Started Nov 2007; status: completed.
02
Drugs
abatacept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00533897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00533897.